

NEUROMUSCULAR BLOCKER STORAGE



EFFECTIVE: 1 March – 1 June 2024

DISCARD CHART ON 1 June 2024 – DOWNLOAD updated chart quarterly →



Store neuromuscular blockers (except vecuronium) at 2 – 8°C until required for use

AFTER REMOVAL FROM REFRIGERATOR for use, adjust expiry and store unused neuromuscular blockers according to advice below

Neuromuscular blocker	Brand and usual storage temperature ¹ (in original packaging)	Stability outside of usual storage temperature ²	After removal from refrigerator NB: mark vial/ ampoule with revised expiry
Atracurium	DBL 2 – 8°C	Not stable outside 2 – 8°C Protect from light	Discard at the end of the day
	Tracrium 2 – 8°C	7 days < 25°C Protect from light	⊘ Do NOT return to fridge Discard after 7 days
Cisatracurium	Juno DBL Nimbex 2 – 8°C	21 days ≤ 25°C Protect from light	⊘ Do NOT return to fridge Discard after 21 days
	Kalcex (distributed by Juno) 2 – 8°C	48 hours ≤ 25°C ³ Protect from light	⊘ Do NOT return to fridge Discard after 48 hours
	AFT 2 – 8°C	1 month ≤ 25°C	⊘ Do NOT return to fridge Discard after 1 month
	Accord 2 – 8°C	Not stable outside 2 – 8°C Protect from light	Discard at the end of the day
Pancuronium	Inresa (SAS) 2 – 8°C	3 months ≤ 25°C ⁴	⊘ Do NOT return to fridge Discard after 3 months
Rocuronium	Esmeron DBL Sandoz 2 – 8°C	12 weeks ≤ 30°C	⊘ Do NOT return to fridge Discard after 12 weeks
	Rocon 2 – 8°C	12 weeks ≤ 25°C	⊘ Do NOT return to fridge Discard after 12 weeks
	Medsurge 2 – 8°C	8 weeks ≤ 25°C	⊘ Do NOT return to fridge Discard after 8 weeks
Suxamethonium	Juno Mercury (S19 supply) 2 – 8°C	30 days ≤ 25°C ^{5,6}	⊘ Do NOT return to fridge Discard after 30 days
Vecuronium	Vecure Sun < 25°C	< 25°C Protect from light	Keep at room temperature Discard after original expiry date

DISCLAIMER

Information was **current at the time of publication – DO NOT** use this chart outside effective dates.
Use QR code to download **quarterly updates** (March, June, September, December) or visit shpa.org.au/NBS
Recommendations are **brand specific**. Please contact manufacturer for advice about unlisted brands.

References: (1) Product Information. (2) Manufacturers were contacted for stability data. (3) Written communication by Juno for Kalcex company (14 Oct 2021). (4) Written communication from Inresa company (17 Feb 2022). (5) Written communication from Juno company (12 Oct 2020). (6) Written communication from Mercury Pharmaceuticals Ltd (15 March 2023).



Compiled by the **SHPA Surgery and Perioperative Medicine Leadership Committee**

PLACE LABEL HERE

Apply label here containing contact details, name and pager number

- Surgery/Perioperative Medicine Pharmacist, and/or
- Pharmacy Department